6h
Hosted on MSNRegeneron: Is It the Perfect Biotech Stock for Value and Growth?CompanyOverview|NASDAQ:REGN] Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major ...
Novavax (NASDAQ:NVAX) shares traded marginally higher on Thursday in the premarket after the Gaithersburg, Maryland-based ...
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.
Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...
1d
Investing News Network on MSNStem Cell Stocks: 10 Biggest NASDAQ Companies in 2025Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...
An FDA advisory committee meeting scheduled next month to decide the composition of next season’s flu vaccines has been ...
Q4 2024 Earnings Call Transcript February 26, 2025 Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.85. Operator: Hello. Welcome to Vir ...
Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...
Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ...
The Trump administration will allocate up to $1B to prevent the spread of bird flu and boost egg imports, Reuters reported, ...
FDA’s Priority Tag to SNY’s Dupixent sBLA for Bullous Pemphigoid Sanofi and Regeneron announced that the FDA has accepted and granted priority review to an sBLA seeking approval of Dupixent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results